title: Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
authors.affiliation: Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80209, USA. david.garfield@earthlink.net
authors.forename: David
authors.initials: D
authors.lastname: Garfield
authors.forename: Aleck
authors.initials: A
authors.lastname: Hercbergs
authors.forename: Paul
authors.initials: P
authors.lastname: Davis
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced* / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000077210:Sunitinib; D013963:Thyroid Hormones / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D013963:Thyroid Hormones; D000077210:Sunitinib